3 August 2017 - CADTH has published its initial recommendation on the use of daratumumab for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.

pERC has recommended the reimbursement of daratumumab conditional upon its cost-effectiveness being improved to an acceptable level and its adoption feasibility being addressed.

Read CADTH initial recommendation for daratumumab